Enhancing Care for Patients with ACS in Mexico: Impact of the Get With The Guidelines®-Coronary Artery Disease Mexico Project at the National Institute of Cardiology
Abstract Body (Do not enter title and authors here): Background: The GWTG initiative has improved global patient care. We introduced GWTG-CAD at Mexico’s largest referral center, the National Institute of Cardiology. This is an independent before/after quality analysis. Hypothesis: Implementing a standardized tool will improve ACS patient management and guideline-recommended therapies. Aims: To compare the center’s data before/after implementing the GWTG-CAD tool registry. Methods: Retrospective, comparative study of ACS patients either transferred from eight referring hospitals or arriving directly to our center. We compared two groups: admissions from July 2022-March 2023 (before) and April 2023-April 2024 (after). Continuous variables are presented as mean±standard deviation or median and interquartile range, based on their distribution. Data: A total of 473 patients, (202 in the before-period and 271 in the after-period). Age, gender, comorbidities and medical history were non-different between groups. The diagnoses included STEMI 73.2% vs. 58.1%, NSTEMI 23.3% vs. 38.8%, UA 3.4% vs. 2.9%. Symptom onset to first medical contact median time was 504(195-972 min) vs. 395(170-688 min), p=0.28. From the before-period, 32.2% underwent pPCI and 61.7% thrombolysis, vs. 46.2% and 42.9% in the after-period. Among all patients, the median time of arrival at referring hospital to PCI was 2,329(356-5142 min) during the before-period vs. 559(164-1702 min) in the after-period (p=0.002). Among STEMI transfers, the time of arrival at referring hospital to PCI was significantly lower (151[110-460] vs. 106[91-142] min, p=0.02). Among direct arrivals, door-to-balloon time was numerically, but not statistically lower (78.5[51-162] vs. 71[45-90] min, p=0.08). Prescription of guideline-recommended therapies from the before-period vs. after-period was DAPT (93.1% vs. 94.1%, p=0.68), ACEI/ARB (83.7% vs. 85.1%, p=0.68), BB (84.8% vs. 89.8%, p=0.10) and statins (97.3% vs. 95.3%, p=0.26). The overall survival rate was (95.5 vs. 97.4%). Conclusions: In this comparative study we observed a significant reduction of transfer to PCI times in all ACS patients after the implementation of the GWTG-CAD project. High prescription of guideline-recommended therapies at discharge were documented.
Najera-rojas, Andrea
( National Institute of Caridology
, Mexico City
, Mexico
)
Arias-mendoza, Alexandra
( National Institute of Caridology
, Mexico City
, Mexico
)
Araiza, Diego
( National Institute of Caridology
, Mexico City
, Mexico
)
Robles-ledesma, Mariana
( National Institute of Caridology
, Mexico City
, Mexico
)
De Los Rios, Manuel
( SINACOR
, Culiacan
, Sinaloa
, Mexico
)
Lugo Gavidia, Leslie Marisol
( Consorcio Academico Mexicano para la obtencion de datos clinicos
, Mexico City
, Mexico
)
Leiva, Jose Luis
( Grupo Intervención San Luis
, San Luis Potosi
, San Luis Potosi
, Mexico
)
De Los Ríos Arce, Luis Fernando
( National Institute of Caridology
, Mexico City
, Mexico
)
Gopar-nieto, Rodrigo
( National Institute of Caridology
, Mexico City
, Mexico
)
Sierra Lara Martinez, Jorge Daniel
( National Institute of Caridology
, Mexico City
, Mexico
)
González Pacheco, Héctor
( National Institute of Caridology
, Mexico City
, Mexico
)
Author Disclosures:
Andrea Najera-Rojas:DO NOT have relevant financial relationships
| Alexandra Arias-Mendoza:No Answer
| Diego Araiza:DO have relevant financial relationships
;
Speaker:Boehringer Ingelheim:Active (exists now)
; Speaker:Viatris:Active (exists now)
; Speaker:Astra Zeneca:Active (exists now)
; Speaker:Novartis:Active (exists now)
; Speaker:Novo Nordisk:Active (exists now)
; Speaker:Adium:Active (exists now)
| Mariana Robles-Ledesma:No Answer
| Manuel De Los Rios:DO NOT have relevant financial relationships
| Leslie Marisol Lugo Gavidia:No Answer
| Jose Luis Leiva:No Answer
| Luis Fernando De los ríos Arce:No Answer
| Rodrigo Gopar-Nieto:DO NOT have relevant financial relationships
| Jorge Daniel Sierra Lara Martinez:No Answer
| Héctor González Pacheco:No Answer